Skip to main content
SpringerLink
Log in

Activation of the high affinity nerve growth factor receptor by two polyanionic chemotherapeutic agents: Role in drug induced neurotoxicity

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Suramin is a polyanionic chemotherapeutic agent which causes severe peripheral neuropathy. The mechanisms of antineoplastic and neurotoxic activities are still poorly understood. Interference with growth factor receptor function has been suggested for suramin's chemotherapeutic function. Previous studies from our laboratory have demonstrated that suramin interfered with the function of nerve growth factor (NGF) and induced lysosomal storage defects within dorsal root ganglion neurons. Pentosan polysulfate (PPS) was used as another polyanionic agent, to compare these two cellular functions; NGF receptor interaction and disruption in glycolipid metabolism. Like suramin and NGF, PPS induced neurite outgrowth from the PC12 cell line which correlated with tyrosine phosphorylation of the high affinity NGF receptor (TrkA/gp140) and ERK-1/MAP kinase. Ultrastructural studies of dorsal root ganglion exposed to PPS for various time periods were normal. This contrasted with suramin exposed cultures which consistently developed lamellar inclusion bodies (LIB) within 6 h. LIB formation with suramin treatment was associated with neuronal cell death, while PPS treatment did not cause any neurotoxic effects. These results indicated that PPS mimicked the effect of suramin on NGF receptors but did not cause similar accumulation of LIB. This suggested that the effect of polyanionic compounds on TrkA was not involved in LIB accumulation and subsequent induction of neurotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hosang M: Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 29: 265-273, 1985

    PubMed  Google Scholar 

  2. Coffey RJ, Leof EB, Shipley GD, Moses HL: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells, J Cell Physiol 132: 143-148, 1987

    PubMed  Google Scholar 

  3. Oliver S, Formento P, Fischel JL, Etienne MC, Milano G: Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur J Cancer 26: 867-871, 1990

    PubMed  Google Scholar 

  4. LaRocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, Dalakas MC: Suramin-induced polyneuropathy. Neurology 40: 954-960, 1990

    PubMed  Google Scholar 

  5. Arora R, Dhand UK, Kobayashi K, Vokes EE, Martin B, Janisch L, Ratain MJ, Soliven B: Evaluation of neuropathy in patients on suramin treatment. Neurology 44(Suppl 2): A306, 1994 Abstract

    Google Scholar 

  6. Russell JW, Windebank AJ, Podratz JL: Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann Neurol 36: 221-228, 1994

    PubMed  Google Scholar 

  7. Gill JS, Hobday KL, Windebank AJ: Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures. Exp Neurol 133: 113-124, 1995

    PubMed  Google Scholar 

  8. Gill JS, Connolly DC, McManus MJ, Maihle NJ, Windebank AJ: Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons. J Neurochem 66: 963-972, 1996

    PubMed  Google Scholar 

  9. Gill JS, Windebank AJ: Suramin is both a partial agonist and competitive inhibitor for the high affinity NGF receptor. Ann Neurol 38: 308, 1995 Abstract

    Google Scholar 

  10. Paul R, Herbert JM, Maffrand JP. Lansen J, Modat G, Pereillo JM, Gordon JL: Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds. Thromb Res 46: 793-801, 1987

    PubMed  Google Scholar 

  11. Combe DR, Parish CR, Ramshaw IA, Snowden IM: Analysis of the inhibition of tumour metastasis by sulphated polysaccharides. Int J Cancer 39: 82-88, 1987

    PubMed  Google Scholar 

  12. MacGregor IR, Dawes J, Pepper DS, Prowse CV, Stocks J: Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides — comparison with effects upon anticoagulant activity, lipolysis and platelet a granule proteins. Thromb Haemost 53: 411-414, 1985

    PubMed  Google Scholar 

  13. Delvos U, Paul JE, Müller-Berghaus G: Effect of the heparinoid pentosan polysulphate (SP 54) on the functional properties of cultured bovine aortic endothelial cells. Blut 51: 127-136, 1985

    PubMed  Google Scholar 

  14. MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M: Metabolism of sodium pentosan polysulphate in man — catabolism of iodinated derivatives. Thromb Haemost 51: 321-325, 1984

    PubMed  Google Scholar 

  15. Nguyen NM, Lehr JE, Pienta KJ: Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 13: 2143-2147, 1993

    PubMed  Google Scholar 

  16. Pienta KJ, Murpphy BC, Isaacs WB, Isaacs JT, Coffey DS: Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. Prostate 20: 233-241, 1992

    PubMed  Google Scholar 

  17. Herbet JM. Cottineau M. Driot F. Pereillo Jm. Maffrand JP: Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migraton induced by acidic and basic FGF in vitro. Biochem Pharmacol 37: 4281-4288, 1988

    PubMed  Google Scholar 

  18. Sydow G, Klöcking H-P: Effect of pentosan polysulfate (SP 54) on the reverse transcriptase activity of several retroviruses. Biomed Biochem Acta 46: 527-530, 1987

    Google Scholar 

  19. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS: The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145: 199-202, 1991

    PubMed  Google Scholar 

  20. Swain S, Wellstein A, Parker B, Lippman M, Steakley C, DeLap R: Heparin-binding growth factor blockade with pentosan polysulfate. Ann N Y Acad Sci 698: 63-70, 1993

    PubMed  Google Scholar 

  21. Wellstein A, Zugmaier G, Califano JA III, Kern F, Paik S, Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 83: 716-720, 1991

    PubMed  Google Scholar 

  22. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 84: 1716-1724, 1992

    PubMed  Google Scholar 

  23. Conti AM, Fischer SJ, Windebank AJ: Inhibition of axonal growth from sensory neurons by excess nerve growth factor. Ann Neurol 1997 (in press)

  24. Windebank AJ, Blexrud MD: Characteristics of neurite outgrowth from rat spinal ganglia: effects of serum and segmental level. J Neuropathol Exp Neurol 45: 683-691, 1986

    PubMed  Google Scholar 

  25. Batistatou A, Greene LA: Internucleosomal DNA cleavage and neuronal cell survival/death. J Cell Biol 122: 523-532, 1993

    PubMed  Google Scholar 

  26. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE: Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499-508, 1989

    PubMed  Google Scholar 

  27. LaRocca RV, Stein CA, Myers CE, Dalakas M, McAtee N: Suramin induced acute polyneuropathy. Proc Annu Meet Am Soc Clin Oncol 8: 71, 1989 Abstract

    Google Scholar 

  28. Stein CA: Suramin: a novel antincoplastic agent with multiple potential mechanisms of action. Cancer Res 53: 2239-2248, 1993

    PubMed  Google Scholar 

  29. Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Goldspiel BR, Adamo D, Cooper MR, Broder S, Yarchoan R: Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 85: 1585-1592, 1993

    PubMed  Google Scholar 

  30. Parker BW, Swain SM, Zugmaier G, DeLap RL, Lippman ME, Wellstein A: Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. J Natl Cancer Inst 85: 1068-1073, 1993

    PubMed  Google Scholar 

  31. Rees S, Constantopoulos G, Barranger JA, Brady RO: Organomegaly and histopathology in an animal model of mucopolysaccharidosis induced by suramin. Naunyn Schmiedebergs Arch Pharmacol 319: 262-270, 1982

    PubMed  Google Scholar 

  32. Constantopoulos G, Rees S, Cragg BG, Barranger JA, Brady RO: Effect of suramin on the activities of degradative enzymes of sphingolipids in rats. Res Commun Chem Pathol Pharmacol 32: 87-97, 1981

    PubMed  Google Scholar 

  33. Constantopoulos G, Rees S, Cragg BG, Barranger JA, Brady RO: Suramin-induced storage disease Mucopolysaccharidosis. Am J Pathol 113: 266-268, 1983

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Neuroscience Program and Mayo Cancer Center, Mayo Clinic and Mayo Foundation, 1501 Guggenheim Building, 200 First Street SW, Rochester, Minnesota, 55905, USA

    Jagjit S. Gill & Anthony J. Windebank

Authors
  1. Jagjit S. Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony J. Windebank
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gill, J.S., Windebank, A.J. Activation of the high affinity nerve growth factor receptor by two polyanionic chemotherapeutic agents: Role in drug induced neurotoxicity. J Neurooncol 40, 19–27 (1998). https://doi.org/10.1023/A:1006051126333

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006051126333

Search

Navigation